Natera acquires Invitae's prenatal and carrier screening assets for $10M upfront

Natera, Inc.

Upfront cash payment of $10 million to Invitae for reproductive health assets.
Additional potential milestone payments of $42.5 million, including cash and litigation-related credits.
Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera.
Acquisition expands Natera's cfDNA testing reach; CEO Steve Chapman cites commitment to service.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.